CRI's Research Update Newsletter

Current Clinical Trials 

In This Issue
STR vs GFR
ION 3
START
Support CRI

Click here to support CRI's lifesaving research

 

Contact Us
For more information about our current research studies:

 

Visit our website at www.crine.org

Call our Boston research team at 617.502.1700

 
May 2013
cri logo and tagline
Because of you, lifesaving HIV and Hepatitis C clinical trials are open and enrolling participants at Community Research Initiative (CRI)

 

CRI is currently offering a number of innovative studies. One of the newest trials investigates a single-tablet regimen for individuals with mild to moderate impairment of kidney function, a common complication in HIV-positive patients. 

 

To view a listing of currrent research trials, click here.

For more information, contact Karen McLaughlin or Julia Green at 617.502.1707 or email [email protected] or [email protected]
 
STR vs. GFR
The STR vs. GFR study evaluates the effect of an experimental single-tablet regimen consisting of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) for HIV-positive individuals with mild to moderate impairment of kidney function. The study will test how well this combination works - and how safe it is - both in those who have never been on treatment and those who are treatment-experienced. Because kidney impairment is a fairly common complication in HIV-positive individuals, this single tablet has the potential to become an important medication in HIV therapy.
ION 3
The ION 3 study is a phase 3 clinical trial for participants with genotype 1 Hepatitis C, without cirrhosis (irreversible scarring of the liver), who have never received treatment for Hepatitis C. The purpose of this study is to evaluate the safety, tolerability, and antiviral efficacy of Sofosbuvir/Ledipasvir (FDC) with or without ribavirin. This study is investigating an oral, direct-acting antiviral experimental study regimen that is half the number of weeks of standard treatments.    
START
START logo
The START (Strategic Timing of Antiretroviral Treatment) study will answer the question, "When should I start taking HIV medication?" Currently guidelines are not consistent as to when the best time to start treatment would be. Some practice guidelines state that it is okay to begin medication when a person's CD4 count reaches 350, while others suggest offering treatment immediately no matter how high the CD4 count is at the time of diagnosis. START is a large, definitive study to determine whether individuals should begin treatment with high CD4 counts (above 500) or whether it is better to wait to start for a CD4 count of around 350.

Community Research Initiative (CRI) is an independent, nonprofit, community-based organization in New England dedicated to HIV clinical research, treatment education, and financial assistance for approved drug treatments and health insurance coverage.

For more information about CRI, please visit our website or
 
     Like us on Facebook   View our videos on YouTube